PubMed HealthSearch

SEARCH · PubMed Health

Results for “SAIDS Vaccines”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Pneumococcal vaccination: perceptions of primary care physicians.

BACKGROUND: Little is known about barriers to pneumococcal vaccination in the primary care setting. METHODS: Mail survey to 405 randomly selected Massachusetts primary care physicians (response rate 68%). RESULTS: Seventy-nine percent considered themselves knowledgeable about current vaccination guidelines, and 75% said vaccination is an important clinical priority. Respondents answered a mean of five of six knowledge questions about vaccination "correctly," that is, consistent with current scientific evidence or expert opinion. Physicians reported high immunization rates: 51% thought over half their eligible patients were vaccinated; however, only 27% thought their colleagues immunized a similar number of patients. Physician attitude was the strongest independent predictor of high reported immunization rates (odds ratio of 4.7, P = 0.0001). Twenty-four percent of respondents thought physician oversight due to the need to attend to other active medical problems greatly reduces the number of patients they immunize. None of eight other financial, administrative, and clinical barriers were felt to be important by more than 7% of physicians. Sixty-six percent of physicians favored a standing order policy to immunize their eligible patients. CONCLUSIONS: Oversight and overestimation of immunization rates appear to be important barriers to pneumococcal vaccination. The literature suggests that reminder and performance feedback systems directed toward eliminating these barriers have had some success; interventions such as standing order policies may yield further improvements and appear to be acceptable to most physicians.

Adult

[A complex vaccine in the prevention of staphylococcal, Pseudomonas aeruginosa and Proteus infections in esophageal cancer patients].

An analysis of clinico-immunological data has demonstrated a considerable decline in non-specific and specific defences against such major factors of hospital infection in esophageal cancer patients as staphylococcal, blue pus and Proteus bacilli. Immunization with a complex vaccine including concentrated staphylococcal anatoxin, blue pus and Proteus vaccines was shown to stimulate the said factors of anti-infectious immunity and to be followed by a 4.7-fold decrease in the incidence of postoperative pyo-inflammatory complications. The said vaccine may be recommended for prevention of infectious complications in cancer patients since its administration is followed by a low-level reaction matched by a marked increase in immunologic vigor.

Antibody Formation

Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus.

Prior infection with a nef-deleted simian immunodeficiency virus (SIV) protects macaques not only against a homologous pathogenic SIV challenge but also against challenge with a chimeric SIV expressing a human immunodeficiency virus type 1 env gene (SHIV). Since this SHIV is itself nonpathogenic, we sought to explore the use of a nonpathogenic SHIV as a live, attenuated AIDS virus vaccine. Four cynomolgus monkeys infected for greater than 600 days with a chimeric virus composed of SIVmac 239 expressing the human immunodeficiency virus type 1 HXBc2 env, tat, and rev genes were challenged intravenously with 100 animal infectious doses of the J5 clone of SIVmac 32H, an isolate derived by in vivo passage of SIVmac 251. Three of the four monkeys became infected with SIVmac. This observation underlines the difficulty, even with a live virus vaccine, in protecting against an AIDS virus infection.

AIDS Vaccines

Live attenuated SIV--a model of a vaccine for AIDS.

The experimental infection of macaques with simian immunodeficiency virus (SIV) has provided strong evidence that it may be possible to develop a vaccine against AIDS. Live attenuated SIV vaccines have been found to confer the most potent protection against challenge with a variety of pathogenic viruses. This article summarizes the work performed at NIBSC to characterize the protection conferred by live attenuated SIV and to identify mechanisms of vaccine protection. The results of these experiments are discussed in conjunction with observations from related studies made by other groups.

AIDS Vaccines

Liposomes as carriers for vaccines.

A liposome vaccine formulation that has been successfully used in both animal immunization studies and clinical trials is described. Issues concerning the choice of components for the liposomal vaccine formulation are discussed, especially with respect to the lipid components and the adjuvant. A procedure is described for manufacturing liposomal vaccines using Good Manufacturing Practices as promulgated by the U.S. Food and Drug Administration. Quality control testing for clinical use is described, with particular emphasis on aspects relevant to liposomes. Utilization issues are discussed, including injection volumes, antigen and adjuvant doses, and routes of administration.

AIDS Vaccines

[Progress in vaccination against AIDS].

Two vaccination trials against AIDS viruses are reported. The first trial was a prophylactic vaccination carried out in the pig-tailed macaque (Macacca nemestrina) against simian immunodeficiency virus (SIV) variant PBj14. The immunogen was a Semliki forest virus (SFV) recombinant expressing SFV - PBj14 envelope protein. Vaccination did not prevent infection but protected the animals against the disease (a fulminant form of AIDS that kills the animal within 12-15 days). The second trial was a therapeutic vaccination carried out with HIV-I-infected hemophilic patients. The immunogen was a toxoïd of alpha interferons. (A toxoïd of alpha interferons is an inactivated and immunogenic preparation of alpha interferons). Vaccination induced the production of neutralizing anti alpha interferon antibody. As a result, circulating alpha interferon concentrations were drastically lowered and the clinical status of patients significantly improved.

AIDS Vaccines